While WEE1 inhibition has been studied previously in ALL, to our knowledge, this is the first report to document the functional importance of WEE1 in primary cultures of relapsed ALL and define it as a potential p53 independent therapeutic target for the improved treatment of high-risk and relapsed ALL. The gene discussed is WEE1; the disease is acute lymphoblastic leukemia.